Business Wire

Nearly Three Quarters of U.S. Travellers Support the Introduction of International Vaccine Passports, According to OAG Research

13.9.2021 16:00:00 EEST | Business Wire | Press release

Share

Travellers are taking to the skies again, but the immediate future of air travel remains highly turbulent, according to OAG’s survey of 1,800-plus U.S. travellers in July and August. Domestic capacity in the U.S. is up 81% from June – August 2021, compared to the same period last year. The increase is being fuelled by strong consumer demand; 70% of consumers surveyed by OAG have booked flights for the future.

While travellers’ willingness to fly is increasing, the Delta variant, increased COVID transmission rates and vaccination preferences weigh heavily on the near and mid-term outlook. The large majority of consumers surveyed by OAG report being fully vaccinated. However, OAG found that only 15% of non-vaccinated individuals plan to get vaccinated before their next trip.

Many airlines and destinations are considering vaccine mandates to strengthen confidence and fight transmission. Sixty-eight percent of all survey respondents said they are interested in or want domestic vaccine passports, and 70% believe vaccine passports should be required for international travel. Alarmingly, of those that said they were not yet vaccinated, 56% said they still wouldn’t get vaccinated even if the airline, airport, or destination required it to travel.

“Vaccine mandates are a polarizing issue. Many airlines, governments and destinations are actively considering mandating vaccines to fly or enter, and the majority of travellers support the use of vaccine passports,” said John Grant, senior analyst at OAG. “While this may add fuel to hot fire, the ongoing strength and resilience of the entire travel market is directly linked to higher vaccination levels and lower transmission rates.”

Other takeaways from OAG’s research include:

  • Continued COVID-19 concerns keep some travellers grounded. Of the 30% of respondents who haven’t booked flights yet, 40% are waiting for vaccination rates and regulations to improve and 30% are waiting for vaccine passports to be required.
  • The business travel outlook remains cloudy. Only 62% of business travellers said their company is planning air travel in the next 12 months, while 38% said their company either has no plans (20%) or has not specified plans (18%).
  • Holiday travel expected to bounce back. The 2021 holiday travel season projects to be a lot stronger than 2020. Of the 38% of travellers surveyed by OAG that said they typically fly for the holidays, only 40% of this group did so in 2020. This year, the percentage of that group who do intend to fly more than doubled (85%). Planned capacity for Thanksgiving week tells a similar story, currently with 47% more domestic seats booked than last year.
  • Booking behaviour remains erratic. Nearly half of travellers surveyed are still booking on short notice (between two weeks to a month in advance), and half are booking between two-six-plus months out. Eighty-eight percent expect ticket prices to rise in the next 12 months.

For the full survey insights, view the report here, https://www.oag.com/us-traveler-survey. To learn more about OAG, visit https://www.oag.com/.

About OAG

OAG is a leading global travel data provider, that has been powering the growth and innovation of the air travel ecosystem since 1929. Headquartered in the UK, OAG has global operations in the USA, Singapore, Japan, Lithuania and China. For more information, visit: www.oag.com and follow us on Twitter @OAG Aviation.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chrissy Azevedo
Corporate Ink for OAG
pressoffice@oag.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye